Updates are available Erratum dated 2021-02-20
Click to view Erratum: https://doi.org/10.1016/s0140-6736(21)00386-x
-
Authors
Logunov, Denis Y
Dolzhikova, Inna V
Shcheblyakov, Dmitry V
Tukhvatulin, Amir I
Zubkova, Olga V
Dzharullaeva, Alina S
Kovyrshina, Anna V
Lubenets, Nadezhda L
Grousova, Daria M
Erokhova, Alina S
Botikov, Andrei G
Izhaeva, Fatima M
Popova, Olga
Ozharovskaya, Tatiana A
Esmagambetov, Ilias B
Favorskaya, Irina A
Zrelkin, Denis I
Voronina, Daria V
Shcherbinin, Dmitry N
Semikhin, Alexander S
Simakova, Yana V
Tokarskaya, Elizaveta A
Egorova, Daria A
Shmarov, Maksim M
Nikitenko, Natalia A
Gushchin, Vladimir A
Smolyarchuk, Elena A
Zyryanov, Sergey K
Borisevich, Sergei V
Naroditsky, Boris S
Gintsburg, Alexander L
- License Information
-
More Information
This article is maintained by: Elsevier
Article Title: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Journal Title: The Lancet
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S0140-6736(21)00234-8
CrossRef DOI link to the associated document: https://doi.org/10.1016/S0140-6736(21)00191-4
Content Type: article
Copyright: © 2021 Elsevier Ltd. All rights reserved.
